Shots:

• The P-I/II study involve assessing of pembrolizumab (IV- 200mg)- Herzuma (biosimilar trastuzumab) (6mg/kg (after 8mg/kg load) D1 and CT in 43 patients with median follow up of 18 mons. In patients with HER2-positive advanced gastric cancer (AGC)
• P-I/II study results: tumor shrinkage of 95.3%- ORR of 76.7%- CR 16.3%- PR 60.5%- disease control rate (DCR) of 97.7%- mPFS 8.6 mos.- mOS 19.3 mos.- mDOR 10.8 mos. and safety
• Herzuma (biosimilar trastuzumab) is a mAb targeted to bind selectively to the extracellular domain of an antigen called HER2 developed to treat adult patients with early breast cancer- metastatic breast cancer- and metastatic gastric cancer approved in Feb 2018 by EMA

Click here to read full press release/ article

 Ref: Celltrion | Image: Celltrion